<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658968</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2015-001933-26</org_study_id>
    <nct_id>NCT02658968</nct_id>
  </id_info>
  <brief_title>Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)</brief_title>
  <official_title>A Phase 1 Dose Finding Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) in Patients With Relapsed/Refractory, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Nanovector</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Nanovector</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory&#xD;
      diffuse large B-cell lymphoma (DLBCL). This is a dose escalating study to define the maximum&#xD;
      tolerable dose of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) in DLBCL patients who&#xD;
      are not eligible for autologous stem cell transplant. The study will also assess safety and&#xD;
      toxicity, pharmacokinetics, biodistribution and efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Actual">July 10, 2021</completion_date>
  <primary_completion_date type="Actual">June 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Maximum Tolerated Dose</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the maximum tolerated dose of Betalutin that can be given to patients with relapsed/refractory, diffuse large B-cell lymphoma, not eligible for autologous stem cell transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The best overall tumour response rate</measure>
    <time_frame>3 months - 2 years</time_frame>
    <description>Efficacy evaluations are measured by tumour response rates using CT and PET/CT imaging with responses classified according to revised response criteria for NHL (Cheson, 2014).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry</measure>
    <time_frame>3 weeks</time_frame>
    <description>Dosimetry will be evaluated by the estimated absorbed radiation dose to target organs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Relapsed, Diffuse Large B-cell Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Betalutin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 MBq/kg b.w., in escalated doses with lilotomab pre-dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betalutin</intervention_name>
    <description>Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.</description>
    <arm_group_label>Betalutin</arm_group_label>
    <other_name>Betalutin, lutetium (177Lu)-lilotomab satetraxetan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged ≥18 years.&#xD;
&#xD;
          2. Histologically confirmed DLBCL (WHO classification).&#xD;
&#xD;
          3. Received at least one prior line of therapy including immuno-chemotherapy.&#xD;
&#xD;
          4. In first or subsequent relapse, or refractory to the last treatment (defined as less&#xD;
             than a complete metabolic response to the last treatment, or within 6 months from the&#xD;
             last treatment).&#xD;
&#xD;
          5. Not suitable for, or declined high dose chemotherapy and autologous stem cell&#xD;
             transplantation (ASCT).&#xD;
&#xD;
          6. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid&#xD;
             malignancy (at least one objectively bi-dimensionally measurable (nodal) lesion (&gt;2 cm&#xD;
             in its largest dimension by CT scan).&#xD;
&#xD;
          7. Negative human anti-murine antibody (HAMA) test.&#xD;
&#xD;
          8. Life expectancy of at least 3 months.&#xD;
&#xD;
          9. Bone marrow tumour infiltration &lt;25% tumour cells.&#xD;
&#xD;
         10. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2&#xD;
&#xD;
         11. Normal organ and bone marrow function defined as:&#xD;
&#xD;
               1. Absolute neutrophil count ≥1.5 x 109/L;&#xD;
&#xD;
               2. Platelet count ≥150 x 109/L;&#xD;
&#xD;
               3. Haemoglobin ≥9 g/dL;&#xD;
&#xD;
               4. Total bilirubin ≤1.5 x upper limit of normal (ULN) (except patients with&#xD;
                  documented Gilbert's syndrome);&#xD;
&#xD;
               5. Liver enzymes: Aspartate transaminase (AST); Alanine transaminase (ALT) or&#xD;
                  Alkaline phosphatase (ALP) ≤2.5 x ULN (or ≤5.0 x ULN if liver involvement by&#xD;
                  primary disease);&#xD;
&#xD;
               6. Adequate renal function as demonstrated by a serum creatinine ≤1.5 mg/dL or a&#xD;
                  creatinine clearance &gt;60 mL/min;&#xD;
&#xD;
               7. Normal coagulation parameters (elevated international normalized ratio (INR),&#xD;
                  prothrombin time or activated partial thromboplastin time (APTT) ≤1.3 ULN range&#xD;
                  acceptable).&#xD;
&#xD;
         12. Women of childbearing potential must&#xD;
&#xD;
               1. understand that the study medication may have teratogenic risk&#xD;
&#xD;
               2. have a negative serum pregnancy test at screening and before Betalutin injection&#xD;
&#xD;
               3. commit to continued abstinence from heterosexual intercourse (excluding periodic&#xD;
                  abstinence or the withdrawal method) or begin two acceptable methods of birth&#xD;
                  control with a Pearl-Index ≤ 1%. without interruption from 4 weeks before&#xD;
                  starting study drug, throughout study drug therapy and for 12 months after end of&#xD;
                  study drug therapy, even if she has amenorrhoea. Apart from abstinence,&#xD;
                  acceptable methods of birth control are:&#xD;
&#xD;
                    -  Combined (estrogen and progestogen containing) hormonal contraception&#xD;
                       associated with inhibition of ovulation&#xD;
&#xD;
                    -  oral&#xD;
&#xD;
                    -  intravaginal&#xD;
&#xD;
                    -  transdermal&#xD;
&#xD;
                    -  Progestogen-only hormonal contraception associated with inhibition of&#xD;
                       ovulation&#xD;
&#xD;
                    -  oral&#xD;
&#xD;
                    -  injectable&#xD;
&#xD;
                    -  implantable&#xD;
&#xD;
                    -  Intrauterine device (IUD)&#xD;
&#xD;
                    -  Intrauterine hormone-releasing system ( IUS)&#xD;
&#xD;
                    -  Bilateral tubal occlusion&#xD;
&#xD;
                    -  Vasectomised partner&#xD;
&#xD;
         13. Male patients must agree to use condoms during intercourse throughout study drug&#xD;
             therapy and the following 12 months.&#xD;
&#xD;
         14. Ability to give written, informed consent prior to any study-specific screening&#xD;
             procedures, with the understanding that the consent may be withdrawn by the patient at&#xD;
             any time without prejudice.&#xD;
&#xD;
         15. Capable of understanding the protocol requirements, is willing and able to comply with&#xD;
             the study protocol procedures, and has signed the informed consent document.&#xD;
&#xD;
         16. A negative Hepatitis B test (HBsAg and anti-HBc) and negative HIV test during&#xD;
             screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior hematopoietic allogenic stem cell transplantation.&#xD;
&#xD;
          2. Prior autologous stem cell transplantation.&#xD;
&#xD;
          3. Previous total body irradiation, or irradiation of &gt;25% of the patient's bone marrow.&#xD;
&#xD;
          4. Prior anti-lymphoma therapy (chemotherapy, immunotherapy or other investigational&#xD;
             agent) within 4 weeks prior to start of study treatment (corticosteroid treatment at&#xD;
             doses of ≤20 mg/day, G-CSF or GM CSF are permitted up to 2 weeks prior to start of&#xD;
             study treatment.). Note: excluding pre-treatment with rituximab as part of this study&#xD;
&#xD;
          5. Patients who are receiving any other investigational agents.&#xD;
&#xD;
          6. Patients with known or suspected central nervous system involvement of lymphoma.&#xD;
&#xD;
          7. History of a previous treated cancer except for the following:&#xD;
&#xD;
               1. adequately treated local basal cell or squamous cell carcinoma of the skin;&#xD;
&#xD;
               2. cervical carcinoma in situ;&#xD;
&#xD;
               3. superficial bladder cancer;&#xD;
&#xD;
               4. localized prostate cancer undergoing surveillance or surgery;&#xD;
&#xD;
               5. localised breast cancer treated with surgery and radiotherapy but not including&#xD;
                  systemic chemotherapy;&#xD;
&#xD;
               6. other adequately treated Stage 1 or 2 cancer currently in complete remission;&#xD;
&#xD;
          8. Pregnant or breastfeeding women.&#xD;
&#xD;
          9. Exposure to another CD37 targeting drug.&#xD;
&#xD;
         10. Allergy to X ray contrast agents.&#xD;
&#xD;
         11. A known hypersensitivity to rituximab, HH1, Betalutin or murine proteins or any&#xD;
             excipient used in rituximab, HH1 or Betalutin.&#xD;
&#xD;
         12. Has received a live attenuated vaccine within 30 days prior to enrolling in the study.&#xD;
&#xD;
         13. Evidence of severe or uncontrolled systemic diseases:&#xD;
&#xD;
               1. uncontrolled infection including evidence of ongoing systemic bacterial, fungal,&#xD;
                  or viral infection (excluding viral upper respiratory tract infections) at the&#xD;
                  time of initiation of study treatment;&#xD;
&#xD;
               2. pulmonary conditions e.g. unstable or uncompensated respiratory disease&#xD;
&#xD;
               3. hepatic, renal neurological or metabolic conditions - which in the opinion of the&#xD;
                  investigator would compromise the protocol objectives.&#xD;
&#xD;
               4. psychiatric conditions e.g. patients unlikely to comply with the protocol, e.g.&#xD;
                  mental condition rendering the patient unable to understand the nature, scope,&#xD;
                  and possible consequences of participating in the study&#xD;
&#xD;
               5. history of erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson&#xD;
                  syndrome;&#xD;
&#xD;
               6. cardiac conditions, including&#xD;
&#xD;
                    -  history of acute coronary syndromes (including unstable angina)&#xD;
&#xD;
                    -  class II, III, or IV heart failure as defined by the New York Heart&#xD;
                       Association (NYHA) functional classification system;&#xD;
&#xD;
                    -  known uncontrolled arrhythmias (except sinus arrhythmia) in the past 24&#xD;
                       weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Illidge, PhD MB BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester, The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego (UCSD) - Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco (UCSF) - Innovation, Technology &amp; Alliances</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Centre</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res. 2013 Jan;33(1):85-95.</citation>
    <PMID>23267131</PMID>
  </reference>
  <reference>
    <citation>Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013 Mar;6(1):20-7.</citation>
    <PMID>23256748</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radioimmunotherapy</keyword>
  <keyword>Lu-177</keyword>
  <keyword>Phase I study</keyword>
  <keyword>Betalutin</keyword>
  <keyword>ARC</keyword>
  <keyword>Antibody Radionuclide Conjugate</keyword>
  <keyword>HH1</keyword>
  <keyword>Rituximab</keyword>
  <keyword>177Lu-DOTA-HH1</keyword>
  <keyword>Lilotomab</keyword>
  <keyword>Lutetium (177Lu)-lilotomab satetraxetan</keyword>
  <keyword>Additional relevant MeSH terms:</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Refractory DLBCL</keyword>
  <keyword>Relapsed DLBCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

